LOC643037 Inhibitors
LOC643037 inhibitors encompass a variety of compounds that target specific signaling pathways potentially related to the function of LOC643037. The first class of inhibitors, including LY294002 and Wortmannin, act by inhibiting PI3K, which is upstream of AKT.the inhibition of AKT phosphorylation through compounds like LY294002 or Wortmannin could impact LOC643037 if it is indeed a downstream target within this pathway. These inhibitors are part of a broader pharmacological approach aimed at modulating signaling pathways, and their effectiveness in influencing LOC643037 relies on the precise biological role of this protein.
Rapamycin, for instance, operates downstream of AKT by targeting mTOR, a key player in regulating cell growth and metabolism. Should LOC643037 be connected to the mTOR pathway, this inhibitor could potentially suppress its function. In a similar vein, triciribine directly inhibits AKT, preventing its activation. Therefore, if LOC643037 is either a substrate of AKT or regulated by it, triciribine could decrease its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
An inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway, LY294002 prevents the activation of AKT, which is a downstream target of PI3K. If LOC643037 is involved in cellular survival or proliferation pathways downstream of AKT, LY294002's effect on PI3K would inhibit LOC643037 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor which acts by binding to the catalytic site of the enzyme irreversibly. It would inhibit LOC643037 by blocking the PI3K/AKT pathway, potentially leading to reduced phosphorylation and activation of downstream targets that may include LOC643037. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This mTOR inhibitor acts by binding to FK506-binding protein (FKBP12) and the resulting complex inhibits mTORC1. Since mTORC1 is involved in protein synthesis and cell growth, inhibition by rapamycin could lead to decreased activity of LOC643037 if it functions downstream of mTORC1 signaling. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
A specific inhibitor of AKT phosphorylation and activation without affecting PI3K, triciribine would inhibit LOC643037 activity by preventing the phosphorylation of AKT, thereby inhibiting any AKT-mediated processes that LOC643037 may be involved in. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
As a cyclin-dependent kinase inhibitor (CDK4/6), PD0332991 would lead to cell cycle arrest. If LOC643037 is involved in the progression of the cell cycle, inhibition of CDK4/6 would prevent its function by halting the cell cycle before the phase where LOC643037 is active. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, SP600125 would inhibit LOC643037 by preventing the activation of the JNK pathway. If LOC643037 is involved in JNK-mediated processes such as apoptosis or inflammation, inhibition of JNK would result in decreased activity of LOC643037. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
An inhibitor of p38 MAPK, SB203580 could inhibit LOC643037 by interfering with the p38 MAPK signaling pathway. If LOC643037 is involved in processes mediated by p38 MAPK, such as stress responses or cytokine production, this inhibition would lead to decreased LOC643037 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that would lead to the reduction of LOC643037 activity by inhibiting the MAPK/ERK pathway, which could be upstream of LOC643037. This would result in decreased signaling through ERK, affecting processes in which LOC643037 is involved. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
A MEK5 inhibitor, BIX 02189 would inhibit LOC643037 by interfering with the MEK5/ERK5 pathway. If LOC643037 relies on the signaling through ERK5 for its activity, then inhibition by BIX 02189 would decrease LOC643037 activity. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
A p70 S6 kinase inhibitor, PF-4708671 would inhibit LOC643037 if its activity is linked to the mTOR/S6K pathway. Inhibition of p70 S6 kinase would prevent the downstream signaling required for processes such as protein synthesis and cell growth, potentially affecting LOC643037 activity. | ||||||